Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase 1 Study Of KTX-1001, An Oral, First-In-Class, Selective, And Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 In Patients With Relapsed And Refractory Multiple Myeloma
Rochester, MN
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
-
Genomic Basis Of Clonal Expansion In Paroxysmal Nocturnal Hemoglobinuria
Rochester, MN
The purpose of this study is to Define genomic landscape in PNH
-
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies And Marrow Toxic Injuries
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.
A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.
Objectives:
To learn more about what makes stem cell transplants and cellular therapies work well such as:
* Determine how well recipients recover from their transplants or cellular therapy;
* Determine how recovery after a transplant or cellular therapy can be improved;
* Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;
* Determine how access to transplant or cellular therapy for different groups of patients can be improved;
* Determine how well donors recover from the collection procedures.
-
PROTOCOL FOR A RESEARCH SAMPLE REPOSITORY FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, OTHER CELLULAR THERAPIES AND MARROW TOXIC INJURIES
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
- Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, and Other Cellular Therapies and Marrow Toxic Injuries
Closed for Enrollment
-
A Phase 1 Study Of KTX-1001, An Oral, First-In-Class, Selective, And Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 In Patients With Relapsed And Refractory Multiple Myeloma
Scottsdale/Phoenix, AZ
Jacksonville, FL
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
-
A Phase 2b, Open-Label, Single-Arm Study Of Selinexor (KPT-330) Plus Low-‑Dose Dexamethasone (Sd) In Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, And An Anti-CD38 Monoclonal Antibody (MAb) Daratumumab, And Refractory To Prior Treatment With Glucocorticoids, An Immunomodulatory Agent, A Proteasome Inhibitor, And An The Anti-CD38 MAb Daratumumab
Scottsdale/Phoenix, AZ
Rochester, MN
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).
-
An Open-Label Phase 1/2 Study Of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, In Subjects With Relapsed Or Refractory Multiple Myeloma
Rochester, MN
The purpose of this study is to determine the safety and effectiveness of JCARH125 in adult subjects with relapsed and/or refractory multiple myeloma. The study will include a Phase 1 part to determine the recommended dose of JCARH125 in subjects with relapsed and/or refractory multiple myeloma, followed by a Phase 2 part to further evaluate the safety and efficacy of JCARH125 at the recommended dose.
-
Observational Registry study of Patients with Paroxysmal Nocturnal Hemoglobinuria treated with Pegcetacoplan
Rochester, MN
The purpose of this study is to establish a registry to characterize the long-term safety of pegcetacoplan in adult patients with PNH, including patients who are treatment naïve, with at
least 5 years of follow-up.
-
Somatic Mutations and Pathobiology of Schnitzler Syndrome
Rochester, MN
This study will perform whole exome sequencing on patients with Schnitzler syndrome to determine whether subclonal mutation are present.
.